Associated tags: Foot, Surgeon, Ankle, Bunion, Patient, TREAC, Conference, Pharmaceutical industry
Locations: PONTE VEDRA, FL, US, UNITED STATES
PONTE VEDRA, Fla., April 09, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty ® and Adductoplasty ® Procedures, today announced that it will release financial results for the first quarter of 2024 after the close of trading on Tuesday, May 7, 2024.
Key Points:
- PONTE VEDRA, Fla., April 09, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty ® and Adductoplasty ® Procedures, today announced that it will release financial results for the first quarter of 2024 after the close of trading on Tuesday, May 7, 2024.
- Company management will host a conference call to discuss financial results beginning at 4:30 pm ET.
- Treace routinely posts information that may be important to investors in the “Investor Relations” section of its website at www.treace.com .
- The Company encourages investors and potential investors to consult the Treace website regularly for important information about Treace.
ABC,
Hypoesthesia,
Patient,
Education,
Foot,
Bunion,
Chronic pain,
Quality of life,
Life,
Surgeon,
Woman,
Arthritis,
Radio,
Diving,
Pain,
Recurrence,
Swelling,
Parent PONTE VEDRA, Fla., March 25, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that 100,000 patients have been treated with its patented Lapiplasty® 3D Bunion Correction® System.1 This milestone coincides with the first-ever National Bunion Day in the United States, which is being sponsored by Treace on April 16, 2024, and the launch of its new patient education and brand awareness campaign.
Key Points:
- “Achieving this important milestone is a testament to the tireless efforts of our team members and the trust of our surgeon customers and patients, all of whom have made our journey possible,” said John T. Treace, CEO and Founder of Treace.
- “Since our initial surgical cases in 2015, Treace has been committed to educating people about surgical options that can provide lasting relief from bunion pain through our innovative procedures that are designed to minimize recovery time, reduce recurrence rates, and improve patient outcomes.
- Today the Company also unveiled its latest campaign to continue to drive patient education and awareness of its Lapiplasty® Procedure.
- Treace will premiere the “Future You” commercial on the finale of “The Bachelor” TV show on March 25, 2024 at 8:00 p.m. Eastern Time on the ABC network.
Retrieved on:
Tuesday, February 27, 2024
Acquisition,
System,
Ankle,
Investment,
Growth,
Surgeon,
Adjustment,
Conference,
GAAP,
American College,
Webcast,
Patent,
Depreciation,
Patient,
Tax,
Net,
G&A,
Trial of the century,
Bank statement,
Video game Gross profit for the fourth quarter of 2023 was $50.7 million, representing an increase of 25% compared to a gross profit of $40.7 million in the fourth quarter of 2022.
Key Points:
- Gross profit for the fourth quarter of 2023 was $50.7 million, representing an increase of 25% compared to a gross profit of $40.7 million in the fourth quarter of 2022.
- Total operating expenses were $57.5 million in the fourth quarter of 2023, compared to total operating expenses of $44.2 million in the fourth quarter of 2022.
- Adjusted EBITDA was $2.6 million in the fourth quarter of 2023 compared to a loss of ($0.5) million for the same period in 2022.
- ET to discuss its fourth quarter and full-year 2023 financial results.
Retrieved on:
Wednesday, February 7, 2024
Company management will host a conference call to discuss financial results beginning at 4:30 pm ET.
Key Points:
- Company management will host a conference call to discuss financial results beginning at 4:30 pm ET.
- A live and archived webcast of the event and investor presentation will be available on the Company’s investor relations website at https://investors.treace.com/ .
- Treace routinely posts information that may be important to investors in the “Investor Relations” section of its website at www.treace.com .
- The Company encourages investors and potential investors to consult the Treace website regularly for important information about Treace.
HVA,
Standard of care,
Surgeon,
IMA,
American College,
DPM,
Trial of the century,
Patient,
Pain,
TSP,
Social,
ACFAS,
Bunion,
Weight-bearing,
Conference,
Nursing PONTE VEDRA, Fla., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced three-year interim clinical data from its ALIGN3D™ post-market study supporting the use of the Lapiplasty® procedure for treating bunions were presented in a podium presentation at the 2024 American College of Foot and Ankle Surgeons (“ACFAS”) Annual Scientific Conference .
Key Points:
- PONTE VEDRA, Fla., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced three-year interim clinical data from its ALIGN3D™ post-market study supporting the use of the Lapiplasty® procedure for treating bunions were presented in a podium presentation at the 2024 American College of Foot and Ankle Surgeons (“ACFAS”) Annual Scientific Conference .
- “We believe these three-year clinical study results set a high standard for a commercial bunion technology and one that further differentiates Lapiplasty® in the marketplace with our surgeons and their patients.
- The Company has submitted its primary endpoint ALIGN3D™ manuscript to a top-tier, peer-reviewed foot and ankle journal at the end of 2023 and expects publication in 2024.
- More information on Treace’s products can be found at www.lapiplasty.com .
Retrieved on:
Thursday, February 1, 2024
“Our continued strong presence at ACFAS underscores Treace's longstanding commitment to investing in the field of foot and ankle surgery,” said John T. Treace, CEO, Founder and Board Member of Treace.
Key Points:
- “Our continued strong presence at ACFAS underscores Treace's longstanding commitment to investing in the field of foot and ankle surgery,” said John T. Treace, CEO, Founder and Board Member of Treace.
- “During this year’s ACFAS conference, we are excited to highlight several new innovations from our robust pipeline of ten focused product launches slated from the second half of 2023 through 2024.
- The Micro-Lapiplasty™ System is now in full commercial release and will be featured in hands-on training workshops at the conference.
- Recently introduced Hammertoe PEEK Fixation System and the LapiTome™ and RazorTome™ single-use osteotomes will also be featured at the conference.
Preliminary revenue of $61.8 million to $62.2 million in the fourth quarter of 2023, an approximate 25% increase at the midpoint over the same period in 2022.
Key Points:
- Preliminary revenue of $61.8 million to $62.2 million in the fourth quarter of 2023, an approximate 25% increase at the midpoint over the same period in 2022.
- Preliminary blended average revenue per Lapiplasty® procedure kit sold in the fourth quarter of 2023 was approximately $6,437, a record high and 9% increase over the same period in 2022.
- Ended the fourth quarter of 2023 with 227 direct quota carrying sales representatives, a 35% increase over year-end 2022 and 82% revenue contribution in the fourth quarter of 2023.
- Following this presentation, Mr. Treace will be joined by Mark Hair, CFO of Treace, for a question-and-answer session.
Retrieved on:
Tuesday, December 19, 2023
PONTE VEDRA, Fla., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that John T. Treace, Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, beginning at approximately 3:45 pm Pacific Time.
Key Points:
- PONTE VEDRA, Fla., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that John T. Treace, Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, beginning at approximately 3:45 pm Pacific Time.
- Treace routinely posts information that may be important to investors in the “Investor Relations” section of its website at www.treace.com .
- The company encourages investors and potential investors to consult the Treace website regularly for important information about Treace.
Retrieved on:
Thursday, November 9, 2023
Foot,
EBITDA,
Acquisition,
Bank statement,
Investment,
Net,
Tax,
Ankle,
Depreciation,
GAAP,
Adjustment,
Growth,
Bunion,
Travel,
Patent,
Pharmaceutical industry,
Video game,
Cryptocurrency,
Bank,
Treace Medical Concepts PONTE VEDRA, Fla., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction® Procedure, today reported financial results for the third quarter ended September 30, 2023.
Key Points:
- PONTE VEDRA, Fla., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction® Procedure, today reported financial results for the third quarter ended September 30, 2023.
- Gross profit for the third quarter of 2023 was $32.8 million, representing an increase of 21% compared to a gross profit of $27.0 million in the third quarter of 2022.
- Total operating expenses were $50.6 million in the third quarter of 2023, compared to total operating expenses of $38.3 million in the third quarter of 2022.
- An investor presentation for the Company’s third quarter 2023 financial results is available in the "Investors" section of Treace's website at investors.treace.com.
PONTE VEDRA, Fla., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction® Procedure, today announced that John T. Treace, Chief Executive Officer, and Mark L. Hair, Chief Financial Officer, will participate in a fireside chat at the Stifel 2023 Healthcare Conference on Tuesday, November 14, 2023, beginning at approximately 8:35 am ET.
Key Points:
- PONTE VEDRA, Fla., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction® Procedure, today announced that John T. Treace, Chief Executive Officer, and Mark L. Hair, Chief Financial Officer, will participate in a fireside chat at the Stifel 2023 Healthcare Conference on Tuesday, November 14, 2023, beginning at approximately 8:35 am ET.
- Treace routinely posts information that may be important to investors in the “Investor Relations” section of its website at www.treace.com .
- The company encourages investors and potential investors to consult the Treace website regularly for important information about Treace.
